Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

The market size of the poly adp-ribose polymerase (parp) inhibitor has experienced swift growth lately. Its size is projected to rise from $8.39 billion in 2024 to $9.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.6%. The expansion during the prior period is due to factors such as clinical studies, regulatory approval, market rivalry, medication combinations, and patient advocacy.

The market size of the poly adp-ribose polymerase (parp) inhibitor is predicted to experience substantial growth in the ensuing years. It is estimated to reach $13.81 billion by 2029, registering a compound annual growth rate (CAGR) of 10.4%. The anticipated growth during the forecast period can be credited to the advancement in indications, personalized healthcare, development of biomarkers, economic considerations in health, and emerging markets. The forecast period is also expected to see trends like precision medicine, improvements in immunotherapy, targeted treatment methods, utilization of artificial intelligence in drug discovery, and healthcare that is focused on patients.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp

What Drivers Are Accelerating Expansion Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

The escalation in ovarian cancer occurrences is forecasted to stimulate the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer is a harmful tumor that emerges in one or both ovaries of a woman, a crucial part of the female reproductive system that generates eggs and female hormones. Factors like genetic predisposition, an aging populace, environmental factors, and hormonal imbalances contribute to the rise in ovarian cancer. Poly ADP-Ribose Polymerase (PARP) Inhibitors are utilized to target DNA repair processes, especially in patients with BRCA alterations, which result in synthetic lethality and improved tumor cell eradication. For example, in February 2024, as per the World Ovarian Cancer Coalition, a non-profit entity based in Canada, the number of females succumbing to ovarian cancer annually is forecasted to surge to 350,956 – a rise of almost 70% from 2022. Hence, the mounting incidence of ovarian cancer is propelling the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market.

What Are The Primary Segmentation Parameters In The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

The poly adp-ribose polymerase (parp) inhibitormarket covered in this report is segmented –

1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types

2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels

3) By Application: Ovarian Cancer; Breast Cancer; Other Applications

4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:

1) By Talazoparib: Talazoparib For Breast Cancer; Talazoparib For Ovarian Cancer; Talazoparib For Prostate Cancer; Talazoparib For Other Cancers

2) By Veliparib: Veliparib For Breast Cancer; Veliparib For Ovarian Cancer; Veliparib For Non-Small Cell Lung Cancer (Nsclc); Veliparib For Other Cancers

3) By Olaparib: Olaparib For Breast Cancer (Her2-negative); Olaparib For Ovarian Cancer (Brca-mutated); Olaparib For Prostate Cancer (Brca-Mutated); Olaparib For Pancreatic Cancer (Brca-Mutated); Olaparib For Other Cancers

4) By Other Drug Types: Niraparib; Rucaparib; Pembrolizumab (Combination Therapy With Parp Inhibitors); Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

Which Emerging Trends Are Reshaping The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Landscape?

Market leaders in the poly ADP-ribose polymerase (PARP) inhibitor industry are focused on creating generic PARP inhibitors to provide personalized treatment alternatives for cancer patients who have certain genetic mutations. These inhibitors are drugs that help to suppress the function of the poly ADP-ribose polymerase (PARP) enzyme. For example, in March 2024, Zydus Lifesciences Limited, a pharmaceutical firm based in India, released Olaparib, a PARP inhibitor marketed under the brand name IBYRA, with the intent of increasing availability to sophisticated cancer therapies. IBYRA is designed to target particular genetic mutations seen in various cancers including breast, ovarian, prostate and pancreatic, thereby offering a customized and efficacious treatment strategy. The drug proves especially profitable for patients with HRD-positive or BRACA mutations, assisting in the slowdown of disease progression.

Which Players Are Shaping The Competitive Landscape Of The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report

What Are The Emerging Regional Trends Driving The Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp

Browse Through More Reports Similar to the Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model